2Stanglmater M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic,caspase-independent apoptotic pathway in B -lymphoid cell lines and in chronic lymphocytic leukemia cell [J]. Ann Hematol,2004,83(10) :634 -645.
4HatoT, Yamanouehi J, Tamura T, et al. Existence of leukemic clones resistant to both imatinib mesylate and retuximab before drug thespies in a patient with Philadelphia chromaosome-postive acute lymphoblstie leukemia[ J].Int J Hematol,2004,80 ( 1 ) :62 - 66.
5Berinstein NL, Grillo-Lopez A J, White CA, et al. Rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].Ann Oncol,1998,9(9) :995 - 1001.
二级参考文献15
1Davis T A,Czerwinski D K,Levy R.Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression[J].Clin Cancer Res,1999,5:611-615.
2Gokbuget N,Hoelzer D.Treatment with monoclonal antibodies in acute lymphoblastic leukemia:current knowledge and future prospects[J].Ann Hematol,2004,83:201-205.
3Coffier B,Lepage E,Briere P D,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma[J].N Engl J Med,2002,346:235-242.
4Czuczman M S,Weaver R,Alkuzweny B,et al.Prolonged clinical and molecular remission in patients with low- grade or follicular nonHodgkin's lymphoma treated with rituximab pus CHOP chemotherapy:9-year follow-up[J].J Clin Oncol,2004,22:4659-4658.
5Davis T A,Grillo-Lopez A J,White C A,et al.Rituximab anti-CD20 monoclonal antibody therapy in non - Hodgkin's lymphoma:safety and efficacy of retreatment[J].J Clin Oncol,2000,18:3135-3143.
6Hato T,Yamanouchi J,Tamura T,et al.Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug thespies in a patient with Philadelphia chromosome-postive acute lymphoblastic leukemia[J].Int J Hematol,2004,80:62-66.
7Vuist W M,Levy R,Maloney D G.Lymphoma regression induced by monoclonal anti-idiotype antibodies correlated with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein[J].Blood,1994,83:899-906.
8Chu P G,Chen Y Y,Molina A,et al.Recurrent B-cell neoplasms after rituximab therapy:an immunophenotypic and genotypic study [J].Leukemia & Lymphoma,2002,43:2335-2341.
9Alvaro-Naranjo T,Jaen-Martinez J,Guma-Padro J,et al.CD-20 negative DLBCL transformation after rituximab treatment in follicular lymphoma:a case report and review of the literature [J].Ann Hematol,2003,82:585-588.
10Berinstein N,Grillo-Lopez A,White C,et al.Rituximab(IDEC-C2B8) concentration and anti- tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin'slymphoma[J].Ann Oncol,1998,9:995-1001.
